EasyBlog

This is some blog description about this site

COPENHAGEN, NOVEMBER 13, 2018 – UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders today announced a partnership between Brown University, Rhode Island Hospital and AntibioTx to join forces in the development of a new treatment for Helicobacter pylori. Morten Sommer, CSO at UNION, commented “We are honored and excited to be working with Professor Mylonakis and his group from Brown University to develop a new treatment with great prospects for patients across the world”

H. pylori is one of the world’s most prevalent pathogens and unless treated, colonization usually has lifelong persistence. Most people with H. pylori colonization never experience symptoms, however, each year millions colonized with H. pylori develop gastrointestinal diseases which are also linked to cancer and mortality. Unfortunately, the increase in antibiotic resistance is reducing effective treatment options, hence highlighting the need for new microbiome sparing alternatives.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, OCTOBER 22, 2018 – UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today announced positive results from a Phase 1 Sensitization Study in 240 healthy adult volunteers with ATx201. The study was conducted in the US under IND as a randomized and placebo-controlled study. In comparing the active group to placebo, no signs of sensitization were observed, and no subjects showed any signs of unexpected adverse events.

Dr. Philippe Prokocimer, Chief Medical Officer of UNION commented: "The positive outcome of the sensitization study complements prior safety studies with ATx201, in both animals and humans. We are pleased that the studies support the safety and tolerability of ATx201 in both healthy and abraded skin".

Dr. Morten Sommer, the Chief Scientific Officer further added: “The safety and tolerability of ATx201 is of paramount importance given our focus on atopic dermatitis which is common in children. We express our genuine appreciation to the volunteers whose time and effort are helping the development of a much needed new treatment option”. ATx201 is currently being tested in atopic dermatitis patients, for which results are soon expected”.

UNION has previously completed two other Phase 1 studies with ATx201. One of them evaluated the ATx201 irritation potential in 36 healthy adult volunteers. All treatment regimens came out with positive results in both intact and abraded skin after daily applications for 21 days. The other Phase 1 study assessed the systemic safety, local tolerability of three dermal formulations of ATx201 in 30 healthy volunteers using a split-body design. The volunteers were treated twice daily with either ATx201 or placebo during a 7-day period. This study also demonstrated good safety as well as low systemic absorption of ATx201.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements

Continue reading

COPENHAGEN, OCTOBER 09, 2018 - Dr. Rasmus Toft-Kehler, Chief Executive Officer of AntibioTx, announced this week in Copenhagen that the company has officially changed its name to UNION therapeutics as of October 5, 2018.

”The new company name – UNION – reflects recent progress on the technology platform and expansion of expertise”, explained Dr. Toft-Kehler, and commented: “Our chemistry platform has provided compounds with very interesting immunological properties in combination with antimicrobial activity. The unique properties of our compounds will enable us to develop innovative treatments across a broad spectrum of diseases” and further adds “the expansion into immunology represents a new era for the company with great prospects for both patients and society”.

UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of molecules exhibiting both antimicrobial and immunomodulatory effects. UNION will initially focus on the treatment of inflammatory skin diseases, however, the chemistry platform and its versatile new modes of action is expected to be applicable across a wide range of diseases. The leadership team of UNION has invented and successfully developed more than 10 FDA-approved medicines. In 2017, these medicines saved thousands of lives and generated revenues of more than 5 Billion USD. UNION is headquartered in Copenhagen (Denmark) with a US subsidiary and a global team.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutic A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, July 30, 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced collaboration with Southern Illinois University in the search of new effective treatments against endometriosis. Dr. Rasmus Toft-Kehler CEO at AntibioTx commented “We are excited about the opportunity to collaborate with Dr. Kanako and her group to elucidate the potential for a novel treatment of endometriosis” to which Dr. Morten Sommer, CSO of AntibioTx further added “We have great confidence in the approach invented by Dr. Kanako and are committed to support this program with a clear aim to bring a new treatment to millions of patients with a very significant and neglected medical need”.

Endometriosis is a common long-term chronic disease that can have a profound impact on women’s physical health and quality of life. Symptoms typically appear when endometrial tissue is found outside the uterus causing significant pain and discomfort. Classic symptoms include intense pelvic pain, dysmenorrhea, dyspareunia and infertility. Malignant transformation of endometriosis may occur in up to 1% of women.  

Occurrence is mostly in women of childbearing age and most frequently in the age group 30-40 years. The prevalence is estimated to be 6-10% in the general female population, although the condition is considered to be underdiagnosed.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, JULY 01 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Umar Hayat, Ph.D. as VP of CMC and Supply Chain.

Dr. Morten Sommer, Chief Scientific Officer of AntibioTx commented: ”As the company continues to expand into new areas the role of CMC becomes increasingly important for our success. We are delighted to have engaged with such a capacity as Umar and are looking very much forward working with him on the team”

Umar Hayat, Ph.D. will be the VP of CMC and Supply Chain at AntibioTx and will, in particular, be responsible for the late-stage clinical part of CMC. Dr. Hayat has more than 18 years of experience in pharmaceutical development, manufacturing and supply chain. He held senior level positions with Relypsa, Anacor and Transcept Pharmaceuticals. Played a pivotal role in the CMC development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis. Umar received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

News